The roles of galectins in hepatic diseases

Area of Science:

• Biochemistry
• Hepatology
• Molecular Biology

Background:

• Hepatic diseases encompass a range of liver conditions including hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
• These diseases often present with subtle symptoms, are challenging to treat, and are associated with high mortality rates globally.
• Aberrant expression of galectins, a family of β-galactoside-binding proteins, is increasingly recognized in the progression of various hepatic diseases.

Purpose of the Study:

• To review and summarize the current research on the multifaceted roles of galectins in the context of hepatic diseases.
• To elucidate the involvement of galectins in conditions such as liver cirrhosis, hepatitis, liver fibrosis, and hepatocellular carcinoma (HCC).
• To provide a theoretical foundation for identifying novel therapeutic targets for hepatic diseases.

Main Methods:

• Literature review of existing studies on galectins and hepatic diseases.
• Analysis of research detailing the expression patterns and functional mechanisms of galectins in liver pathology.
• Synthesis of findings regarding galectin involvement in intracellular and extracellular hepatic disease regulation.

Main Results:

• Abnormal galectin expression is a common feature across diverse hepatic diseases, including liver fibrosis, hepatitis, cirrhosis, and HCC.
• Galectins regulate hepatic disease progression through interactions involving their carbohydrate recognition domain and hepatocyte glycoconjugates.
• Their functions extend to both intracellular and extracellular roles in modulating liver disease pathogenesis.

Conclusions:

• Galectins play significant and varied roles in the development and progression of major hepatic diseases.
• Targeting galectins presents a promising avenue for the development of novel therapeutic strategies for liver conditions.
• Further research into galectin biology is warranted to fully exploit their potential in treating hepatic diseases.